
|Videos|July 4, 2022
Prostate cancer disparities have deepened since USPSTF negative screening recommendation
Author(s)Urology Times staff
“Patients who really need to be screened are not getting screened,” says Ram Pathak, MD.
Advertisement
In this video, Ram Pathak, MD, an assistant professor at Mayo Clinic, discusses how the United States Preventative Services Task Force (USPSTF) grade D recommendation against PSA screening has resulted in a disproportionate increase in the incidence of metastatic prostate cancer among minority populations at screening.
At the 2022 AUA Annual Meeting, Pathak shared the abstract, “Racial and ethnic disparities magnified after USPSTF category D recommendation for PSA screening.”
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Higher intake of ultra-processed food associated with increased prostate cancer risk
2
Jessica Yih, MD, highlights data on testosterone therapy in women
3
Real-world data support PSA below 0.2 ng/mL as key response threshold in mCSPC
4
Narmina Khanmammadova, MD, discusses findings on pelvic floor therapy before HoLEP
5









